Results 101 to 110 of about 7,321 (205)

Maraviroc susceptibility of parental and site-directed mutagenesis Env clones.

, 2018
Maraviroc susceptibility of parental and site-directed mutagenesis Env clones.
Charles Craig (52348), Wei Huang (36889), Mike Westby (2238055), Paul Simpson (528063), David L. Robertson (64202), Marilyn Lewis (199665), Jonathan Toma (6157130), Mike Mosley (6157133), Julie Mori (3389570), Roy Mansfield (6157136), Elna van der Ryst (6157139), Jeannette M. Whitcomb (161996)   +11 more
core   +1 more source

Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial

BMC Neurology
Background Post-stroke depression (PSD) is a significant impediment to successful rehabilitation and recovery after a stroke. Current therapeutic options are limited, leaving an unmet demand for specific and effective therapeutic options.
Oren Tene, Jeremy Molad, Ofer Rotschild, Aviva Alpernas, Muhamad Hawwari, Estelle Seyman, Nir Giladi, Hen Hallevi, Einor Ben Assayag   +8 more
doaj   +1 more source

PREPARATION AND EVALUATION OF MARAVIROC MUCOADHESIVE MICROSPHERES FOR GASTRO RETENTIVE DRUG DELIVERY [PDF]

, 2015
Objective: The objective of this research was to formulate and evaluate pectin and HPMC different grades mucoadhesive microspheres in combination with sodium alginate for controlled release of maraviroc.Methods: The maraviroc mucoadhesive microspheres ...
Ali, Mohamed Ashraf, Velmurugan, Sellappan   +1 more
core  

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

, 2011
The effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d.
Noella Ndongo, Caroline Ridgway, Rebecca Mack, Samantha Abel, Julia Hamlin, Sarah Tweedy, Thomas N. Kakuda, John Davis, Monika Schöller-Gyüre, Wendy Petit, Vanitha Sekar, Richard M. W. Hoetelmans   +11 more
core   +1 more source

Maraviroc [PDF]

, 2020
openaire   +1 more source

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1

, 2017
Maraviroc is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics, safety, and efficacy of maraviroc in combination with optimized background therapy (OBT) in ...
Marinella Della Negra, Fang, Annie, Valluri, Srinivas Rao, van der Ryst, Elna, Annie Fang, Giaquinto, Carlo, Jayvant Heera, Fourie, Jan, Elna van der Ryst, Mawela, Muthuhadini Patience, McFadyen, Lynn, Chokephaibulkit, Kulkanya, Lynn McFadyen, Carlo Giaquinto, Craig, Charles, Jan Fourie, Rebecca Yanhui Zhang-Roper, Charles Craig, Srinivas Rao Valluri, Negra, Marinella Della, Clark, Andrew, Zhang-Roper, Rebecca Yanhui, Mitha, Ismail Haroon, Kulkanya Chokephaibulkit, Vourvahis, Manoli, Heera, Jayvant, Manoli Vourvahis, Ismail Haroon Mitha, Andrew Clark, Muthuhadini Patience Mawela   +29 more
core   +1 more source

Blockade of CCR5+ T Cell Accumulation in the Tumor Microenvironment Optimizes Anti‐TGF‐β/PD‐L1 Bispecific Antibody

Advanced Science
In the previous studies, anti‐TGF‐β/PD‐L1 bispecific antibody YM101 is demonstrated, with superior efficacy to anti‐PD‐L1 monotherapy in multiple tumor models.
Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Bin Zhao, Zhuoyang Shen, Shengtao Hu, Chaomei Zhang, Xiaojun Zhang, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Qian Chu, Zhijun Dai, Kongming Wu   +14 more
doaj   +1 more source

Clinical use of CCR5 inhibitors in HIV and beyond

Journal of Translational Medicine, 2010
Since the discovery of CCR5 as a coreceptor for HIV entry, there has been interest in blockade of the receptor for treatment and prevention of HIV infection.
Gilliam Bruce, Riedel David, Redfield Robert   +2 more
doaj  

Maraviroc for Stroke Recovery (MASTER): protocol for a phase 2 double-blind placebo-controlled randomised clinical trial. [PDF]

BMJ Open
Broc N, Byczynski G, Dirren E, Carrera E.   +3 more
europepmc   +1 more source

Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. [PDF]

Signal Transduct Target Ther
Suarez-Carmona M, Hampel M, Zhang XW, Pöchmann A, Grauling-Halama SA, Valous NA, Charoentong P, Ferber D, Wissfeld J, Höflich A, Goriely S, Detavernier A, Azouz A, Rongvaux A, Zukunft S, Fleming I, Okun JG, Baracos V, Heikenwalder M, Zitvogel L, Xu X, Xu C, Volkmar M, Schraivogel D, Steinmetz L, Hamanishi J, Mandai M, Gaida M, Mokry T, Nattenmüller J, Sedlaczek O, Monje N, Schwab R, Hasenburg A, Mavratzas A, Boger RJ, Marmé F, Schott S, Halama N.   +38 more
europepmc   +1 more source